Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2016 2
2017 2
2018 1
2019 1
2020 2
2021 2
2022 3
2023 2
2024 3
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
A proposal for a comprehensive approach to infections across the surgical pathway.
Sartelli M, Pagani L, Iannazzo S, Moro ML, Viale P, Pan A, Ansaloni L, Coccolini F, D'Errico MM, Agreiter I, Amadio Nespola G, Barchiesi F, Benigni V, Binazzi R, Cappanera S, Chiodera A, Cola V, Corsi D, Cortese F, Crapis M, Cristini F, D'Arpino A, De Simone B, Di Bella S, Di Marzo F, Donati A, Elisei D, Fantoni M, Ferrari A, Foghetti D, Francisci D, Gattuso G, Giacometti A, Gesuelli GC, Marmorale C, Martini E, Meledandri M, Murri R, Padrini D, Palmieri D, Pauri P, Rebagliati C, Ricchizzi E, Sambri V, Schimizzi AM, Siquini W, Scoccia L, Scoppettuolo G, Sganga G, Storti N, Tavio M, Toccafondi G, Tumietto F, Viaggi B, Vivarelli M, Tranà C, Raso M, Labricciosa FM, Dhingra S, Catena F. Sartelli M, et al. Among authors: d arpino a. World J Emerg Surg. 2020 Feb 18;15(1):13. doi: 10.1186/s13017-020-00295-3. World J Emerg Surg. 2020. PMID: 32070390 Free PMC article. Review.
A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy.
Luminari S, Pinto A, Puccini B, D'Arpino A, Omodeo Salè E, Bellone M, Pradelli L, Sabinot A. Luminari S, et al. Among authors: d arpino a. Clinicoecon Outcomes Res. 2025 Apr 16;17:335-348. doi: 10.2147/CEOR.S509907. eCollection 2025. Clinicoecon Outcomes Res. 2025. PMID: 40256614 Free PMC article.
The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Metro G, Ricciuti B, Brambilla M, Baglivo S, Soli I, Minenza E, Leonardi GC, D'arpino A, Colabrese D, Tazza M, Zicari D, Minotti V, Chiari R. Metro G, et al. Among authors: d arpino a. Expert Opin Drug Saf. 2017 Jan;16(1):101-109. doi: 10.1080/14740338.2017.1267725. Epub 2016 Dec 11. Expert Opin Drug Saf. 2017. PMID: 27910704 Review.
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry.
De Luca L, Formigli D, Meessen J, Uguccioni M, Cosentino N, Paolillo C, Di Lenarda A, Colivicchi F, Gabrielli D, Gulizia MM, Scherillo M; START Investigators. De Luca L, et al. Eur Heart J Qual Care Clin Outcomes. 2021 Sep 16;7(5):513-520. doi: 10.1093/ehjqcco/qcaa054. Eur Heart J Qual Care Clin Outcomes. 2021. PMID: 32559279
A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy.
Bellone M, Sabinot A, D'Arpino A, Salè EO, Ghislieri D, Pradelli L. Bellone M, et al. Among authors: d arpino a. Glob Reg Health Technol Assess. 2024 Dec 9;11:239-247. doi: 10.33393/grhta.2024.3170. eCollection 2024 Jan-Dec. Glob Reg Health Technol Assess. 2024. PMID: 39659736 Free PMC article.
19 results